(NASDAQ:JG), SHENZHEN, China, Feb. 06, 2026 (GLOBE NEWSWIRE) — Aurora Mobile (NASDAQ: JG) (“Aurora Mobile” or the “Company”), a leading provider of customer engagement and marketing technology services in China, today announced that its leading AI-driven customer engagement platform, EngageLab, has entered into a strategic partnership with Blurams Tec Limited (“Blurams”), a smart video cloud […]

Bitcoin Everlight is drawing comparisons to Bitcoin's early participation phase as its public presale continues through Phase 2, with total contributions now exceeding $250,000. SAN FRANCISCO, Feb. 06, 2026 (GLOBE NEWSWIRE) — Bitcoin Everlight confirmed that its multi-stage public presale remains active, with Phase 2 priced at $0.0010 approaching completion. The current stage of participation

(NASDAQ:ROIV),(NasdaqGM:ROIVW), Brepocitinib 45 mg significantly improved cutaneous sarcoidosis disease activity, achieving a 22.3-point improvement in mean CSAMI-A at Week 16 versus a 0.7-point improvement in placebo (D21.6 P<0.0001). Brepocitinib demonstrated rapid, deep and sustained improvements across all other efficacy endpoints measured with consistent safety profile Priovant plans to progress CS to a pivotal program with

(NasdaqGM:SHLS), PORTLAND, Tenn., Feb. 06, 2026 (GLOBE NEWSWIRE) — Shoals Technologies Group, Inc. (“Shoals” or the “Company”) (Nasdaq: SHLS), a global leader in electrical infrastructure solutions for the energy transition market, announced today its participation in the following upcoming investor events: February 26, 2026: Guggenheim Virtual Fireside Chat Shoals' CEO, Brandon Moss, and CFO, Dominic

(NASDAQ:IMVT), IMVT-1402 potentially registrational trial in difficult-to-treat rheumatoid arthritis (D2T RA) fully enrolled, with topline data expected in the second half of calendar year 2026; topline data from the proof-of-concept trial in cutaneous lupus erythematosus (CLE) expected in the second half of calendar year 2026 IMVT-1402 development is progressing with potentially registrational studies in Graves'

(NASDAQ:ROIV),(NasdaqGM:ROIVW), Brepocitinib 45 mg significantly improved cutaneous sarcoidosis disease activity, achieving a 22.3-point improvement in mean CSAMI-A at Week 16 versus a 0.7-point improvement in placebo (D 21.6 P<0.0001) All brepocitinib 45 mg patients achieved a clinically meaningful response, with 100% demonstrating at least a 10-point improvement on CSAMI-A On the Investigator's Global Assessment (IGA),

(TSX:BITF),(NasdaqGM:BITF), TORONTO, Ontario and NEW YORK, Feb. 06, 2026 (GLOBE NEWSWIRE) — Bitfarms Ltd. (NASDAQ/TSX: BITF) (“Bitfarms” or the “Company”), a North American digital infrastructure and energy company, today announced that its Board of Directors has approved a plan of arrangement (the “Arrangement”) under which the Company will redomicile from Canada to the United States

(NASDAQ:CBUS), Cibus to utilize proprietary Rapid Trait Development System(TM) to enable development of durable resistance to Light Leaf Spot disease, which has caused estimated yield losses of up to £300m in recent years SAN DIEGO, Feb. 06, 2026 (GLOBE NEWSWIRE) — Cibus, Inc. (Nasdaq: CBUS) (the “Company” or “Cibus”), a leading agricultural technology company that

(NasdaqGM:VHCPU), Fort Lauderdale, Florida, Feb. 06, 2026 (GLOBE NEWSWIRE) — Vine Hill Capital Investment Corp. II (Nasdaq: VHCPU) (the “Company“), a special purpose acquisition company, today announced that, commencing on February 9, 2026, holders of the units (the “Units“) sold in the Company's initial public offering may elect to separately trade the Company's Class A

(CNSX:PRME.CN), MONTREAL, Feb. 06, 2026 (GLOBE NEWSWIRE) — Prime Drink Group Corp. (CSE: PRME) (“Prime” or the “Company“) is pleased to announce that it has secured exclusive licenses from Prime Capital Investments Inc. for the rights to certain Beach Day Every Day (“BDED“) trademarks, in exchange for royalties and marketing and promotion fees. These licenses